Events
AASLD
8-12 November, 2019
Boston, Massachusetts
ENYO Pharma attended the AASLD meeting in Boston and presented four posters as well as performed an oral presentation around FXR agonists in HBV and NASH.
During the conference, ENYO Pharma sponsored a Symposium to discuss recent advances in the understanding of the replication of Hepatitis B (HBV) and the potential ability of Farnesoid X receptor (FXR) agonists, such as EYP001, to provide a functional cure for HBV.
Targeting Immunometabolism in Autoimmune Diseases and Inflammation conference
22 October, 2019
New-York, USA
ENYO Pharma will participate to the “Targeting Immunometabolism in Autoimmune diseases and Inflamamtion conference” in New York and will present a poste entitled “A novel small molecule modulating mitochondrial activity improves inflammation in a diet-induced NASH model”
International HBV Meeting
1-5 October, 2019
Melbourne, Australia
The ENYO Pharma team will be present in Melbourne in October to present, in collaboration with Pr. André’s Inserm team, a poster entitled “Interplay and Recruitment of FXR and HBx on cccDNA and Role on Viral Transcription” describing FXR mechanism of action in HBV inhibition.
2019 EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY conference
27th of Sept – 1st of Oct
Barcelona, Spain
ENYO Pharma will attend the ESMO conference in order to raise awareness of it novel, potent chemistry which induces Immunogenic Cell Death in multiple tumour types and inhibits tumor growth in animal models.
“Nordic Life Science” partnering conference
10-12 September, 2019
Malmö, Norway
ENYO Pharma will attend the Nordic Life Science Partnering conference in Mälmo to present its projects, technologies and partnering opportunities. At the same conference, ENYO will also participate in a panel discussion hosted by Charles River where several companies will share their experiences on fee for service partnering in drug discovery.
Latest Press Release 